Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?—a systematic review and meta-analysis
- 817 Downloads
This systematic review evaluates the efficacy of neurokinin-1 receptor antagonists (NK1RAs) for the prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy (MEC) excluding anthracycline-cyclophosphamide-based regimens.
A systematic review of MEDLINE (via PubMed and OVID) and Central databases, plus major oncology conferences, identified randomized trials evaluating NK1RAs in combination with a 5-HT3 RA plus a glucocorticoid for management of CINV. Efficacy endpoints were complete response (CR), no emesis and no nausea rates. Data were analyzed using a random effects model.
Sixteen trials (3848 patients) were identified. Results were separately analyzed for (a) pure MEC regimens (excluding regimens containing carboplatin or oxaliplatin), (b) carboplatin-based regimens, and (c) oxaliplatin-based regimens. (a) Two trials (abstracts) enrolled 715 patients. The odds ratio for overall CR with the addition of an NK1-RA was 1.46 (95% 1.06–2.02; p = 0.02) with an absolute risk difference (RD) of 8%. (b) Nine trials (1790 patients) were identified. The OR for achieving an overall CR was 1.96 (95% CI 1.57–2.45; p < 0.00001) in favor of the NK1RA containing regimen with an RD of 15%. (c) Three trials (1190 patients) were identified. The OR for achieving an overall CR was 1.34 (95% CI 0.88–2.04; p = 0.17) not reaching statistical significance with a RD of 4%.
Clear clinically significant benefit was seen with the addition of NK1RAs in carboplatin-based chemotherapy. A global benefit of an NK1RA containing regimen for the whole MEC category cannot be attested yet and warrants more randomized trials exclusively testing pure MEC regimens without carboplatin.
KeywordsNeurokinin-1 receptor antagonist (NK1RA) Chemotherapy-induced nausea and vomiting (CINV) Moderately emetogenic chemotherapy (MEC) Carboplatin Oxaliplatin
According to ICMJE, the authors made the following contributions. Literature search: KJ, LB, FJ; quality assessment: KJ, LB, AH, FJ; data extraction: KJ, LB, FJ; statistical analysis: LB, AH; manuscript writing: KJ, LB, AH, CMT, FJ; overview of the study: KJ, LB, AH, CMT, FJ. All authors gave final approval for submission of the manuscript.
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
Karin Jordan has received honoraria and travel and accommodation expenses from and has served on advisory boards for Merck & Co., Inc., Helsinn and Tesaro. Axel Hinke has received research funding from Merck & Co., Inc. Franziska Jahn has received honoraria and travel and accommodation expenses from and has served on advisory boards for MSD and Tesaro. Luisa Blättermann and Carsten Müller-Tidow declare no conflict of interest.
Statement for primary data use
The review used published primary data from individual trials. The journal is allowed to review the used primary data if requested.
- 1.ABIM (2013) Choosing wisely: ten things physicians and patients should question. http://www.choosingwisely.org/doctor-patient-lists/american-society-of-clinical-oncology in: editor (ed)^(eds) Book choosing wisely: ten things physicians and patients should question. http://www.choosingwisely.org/doctor-patient-lists/american-society-of-clinical-oncology City
- 2.Aridome K, Mori SI, Baba K, Yanagi M, Hamanoue M, Miyazono F, Tokuda K, Imamura H, Ogura Y, Kaneko K, Kijima F, Maemura K, Ishigami S, Natsugoe S (2016) A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. Mol Clin Oncol 4:393–398CrossRefGoogle Scholar
- 3.Escobar Y, Cajaraville G, Virizuela JA, Alvarez R, Munoz A, Olariaga O, Tames MJ, Muros B, Lecumberri MJ, Feliu J, Martinez P, Adansa JC, Martinez MJ, Lopez R, Blasco A, Gascon P, Calvo V, Luna P, Montalar J, Del Barrio P, Tornamira MV (2015) Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (actual data of vomiting incidence by chemotherapy evaluation) study. Support Care Cancer 23:2833–2840CrossRefGoogle Scholar
- 4.Gralla R, Jordan K, Rapoport B, Street JC, Carides A (2010) Assessing the magnitude of antiemetic benefit with the addition of the NK1 receptor antagonist (NK1) aprepitant for all platinum agents: analysis of 1,872 patients (pts) in prospective randomized clinical phase III trials (RCTs). J Clin Oncol 28:9057CrossRefGoogle Scholar
- 5.Hesketh PJ (1997) Methodology of antiemetic trials. Consensus conference on antiemetic therapy Extanded abstract book, Perugia, Italy April 28-29: 135–141Google Scholar
- 9.Hesketh PJ, Schwartzberg L, Modiano M, Arora S, Poma A, Schnading I (2015) Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting (CINV) in moderately emetogenic chemotherapy (MEC) J Clin Oncol Suppl: #9622Google Scholar
- 10.Hesketh PJ, Wright O, Rosati G, Russo M, Levin J, Lane S, Moiseyenko V, Dube P, Kopp M, Makhson A (2012) Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer 20:1471–1478CrossRefGoogle Scholar
- 11.Ito Y, Karayama M, Inui N, Kuroishi S, Nakano H, Nakamura Y, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Hayakawa H, Suda T, Chida K (2014) Aprepitant in patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy lung cancer (Amsterdam, Netherlands) 84: 259-264CrossRefGoogle Scholar
- 16.Kusagaya H, Inui N, Karayama M, Fujisawa T, Enomoto N, Kuroishi S, Nakamura Y, Matsuda H, Yokomura K, Koshimizu N, Toyoshima M, Imokawa S, Yamada T, Shirai T, Hayakawa H, Suda T (2015) Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer lung cancer (Amsterdam, Netherlands) 90: 410−416Google Scholar
- 20.NCCN (2016) National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology. Antiemesis. Version 1.2016. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#antiemesis. In: editor (ed)^(eds) book National Comprehensive Cancer Network, Inc. NCCN clinical practice guidelines in oncology. Antiemesis. Version 1.2016. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#antiemesis. National Comprehensive Cancer Network Web site., City
- 21.Nishimura J, Satoh T, Fukunaga M, Takemoto H, Nakata K, Ide Y, Fukuzaki T, Kudo T, Miyake Y, Yasui M, Morita S, Sakai D, Uemura M, Hata T, Takemasa I, Mizushima T, Ohno Y, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M, Multi-center Clinical Study Group of Osaka CCTG (2015) Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 51:1274–1282CrossRefGoogle Scholar
- 22.Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll HJ (2010) Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer 18:423–431CrossRefGoogle Scholar
- 23.Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, Group EMGW (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243CrossRefGoogle Scholar
- 24.Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MECCC (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27:v119–v133CrossRefGoogle Scholar
- 26.Schwartzberg LS, Modiano MR, Rapoport BL, Chasen MR, Gridelli C, Urban L, Poma A, Arora S, Navari RM, Schnadig ID (2015) Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 16:1071–1078CrossRefGoogle Scholar
- 27.Takahashi T, Nakamura Y, Tsuya A, Murakami H, Endo M, Yamamoto N (2011) Pharmacokinetics of aprepitant and dexamethasone after administration of chemotherapeutic agents and effects of plasma substance P concentration on chemotherapy-induced nausea and vomiting in Japanese cancer patients Cancer Chemother Pharmacol 68: 653–659CrossRefGoogle Scholar
- 28.Tanioka M, Kitao A, Matsumoto K, Shibata N, Yamaguchi S, Fujiwara K, Minami H, Katakami N, Morita S, Negoro S (2013) A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 109:859–865CrossRefGoogle Scholar
- 29.Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL (2016) Exploration of the heterogeneity of moderately Emetogenic chemotherapy on response to Fosaprepitant in a randomized phase III trial. In: editor (ed)^(eds) book exploration of the heterogeneity of moderately Emetogenic chemotherapy on response to Fosaprepitant in a randomized phase III trial. Annals of Oncology 27, Suppl 6: #1453O, City, pp. 1453OGoogle Scholar
- 30.Weinstein C, Jordan K, Green SA, Camacho E, Khanani S, Beckford-Brathwaite E, Vallejos W, Liang LW, Noga SJ, Rapoport BL (2016) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 27:172–178CrossRefGoogle Scholar
- 31.Yahata H, Kobayashi H, Sonoda K, Shimokawa M, Ohgami T, Saito T, Ogawa S, Sakai K, Ichinoe A, Ueoka Y, Hasuo Y, Nishida M, Masuda S, Kato K (2016) Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 21:491–497CrossRefGoogle Scholar